收费全文 | 70篇 |
免费 | 2篇 |
儿科学 | 2篇 |
基础医学 | 7篇 |
临床医学 | 4篇 |
内科学 | 14篇 |
皮肤病学 | 2篇 |
神经病学 | 18篇 |
外科学 | 8篇 |
预防医学 | 9篇 |
药学 | 8篇 |
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 5篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 2篇 |
2014年 | 2篇 |
2013年 | 2篇 |
2012年 | 2篇 |
2011年 | 6篇 |
2010年 | 9篇 |
2009年 | 5篇 |
2008年 | 4篇 |
2007年 | 3篇 |
2006年 | 8篇 |
2005年 | 3篇 |
2004年 | 2篇 |
2003年 | 2篇 |
2002年 | 2篇 |
2001年 | 1篇 |
1997年 | 1篇 |
1984年 | 1篇 |
1981年 | 1篇 |
1979年 | 1篇 |
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Objectives: A cost-utility analysis (CUA) has been conducted to evaluate the efficiency of nintedanib, in comparison to all available alternatives, in a French setting using the official methodological guidelines.
Methods: A previously developed lifetime Markov model was adapted to the French setting by simulating the progression of IPF patients in terms of lung function decline, incidence of acute exacerbations, and death. Considering the effect of IPF on patients’ quality-of-life, a CUA integrating quality adjusted life years (QALY) was chosen as the primary outcome measure in the main analysis. One-way, probabilistic, and scenario sensitivity analyses were performed to evaluate the robustness of the model.
Results: Treatment with nintedanib resulted in an estimated total cost of €76,414 (vs €82,665 for pirfenidone). In comparison with all other available options, nintedanib was predicted to provide the most QALY gained (3.34 vs 3.29). This analysis suggests that nintedanib has a 59.0% chance of being more effective than pirfenidone and s 77.3% chance of being cheaper than pirfenidone. Sensitivity analyses showed the results of the CUA to be robust.
Conclusions: In conclusion, this CUA has found that nintedanib appears to be a more cost-effective therapeutic option than pirfenidone in a French setting, due to fewer acute exacerbations and a better tolerability profile. 相似文献